Leading the way to safer medication
 Crosscheck  Recommender

Aprepitant

Brand names: ATANTO CINVANTI EMEND

Therapeutic Indications

Aprepitant is indicated for:

Prevention of nausea and vomiting associated with chemotherapy

Irrespective of gender only Adults (18 years old or older)

Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 80-125 mg once daily

Prevention of nausea and vomiting associated with chemotherapy

Irrespective of gender only Adolescents (12 years - 18 years old)

Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adolescents from the age of 12.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 80-125 mg once daily

Contraindications

Active ingredient Aprepitant is contraindicated in the following cases:

Pimozide, terfenadine, astemizole, cisapride

No gender/age discrimination

Co-administration with pimozide, terfenadine, astemizole or cisapride is contraindicated.